trending Market Intelligence /marketintelligence/en/news-insights/trending/kj8Ogzd9AZ01wYuSCDr5tA2 content esgSubNav
In This List

Dynavax reports positive phase 1b/2 data for skin cancer treatment

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Dynavax reports positive phase 1b/2 data for skin cancer treatment

Dynavax Technologies Corp. reported positive results from the dose escalation phase of an ongoing phase 1b/2 study for its drug SD-101 in combination with Merck & Co. Inc.'s Keytruda in patients with metastatic melanoma, or skin cancer.

In 7 anti-PD-1/L1-naïve patients, SD-101 used in combination with Keytruda resulted in a 100% overall response rate and a 29% complete response rate, versus Keytruda as monotherapy which showed 33% overall response rate and a 6% complete response.

In 12 patients with advanced melanoma who had failed anti-PD-1 treatment, the introduction of SD-101 caused tumor shrinkage in 42% patients, with 17% having a partial response, indicating an anti-tumor immune response generated by SD-101.

The drug combination mobilized both innate and adaptive immune response in study participants. Tumor shrinkage was also observed in non-injected visceral lesions.